Editor’s note: An earlier version of this story referred to XtalPi as a biotech firm. The company has clarified that it belongs to the pharmaceutical technology sector.
XtalPi, a SoftBank-backed Chinese unicorn that applies AI techniques for drug development, is planning to establish a research base in Hong Kong. The Shenzhen-based pharmatech firm is also setting up an investment fund called 42 Capital Partners, a senior executive told DealStreetAsia.
